Analyst Consensus ?
ConsensusBuy51 ratings
Bullish2752.9%
Neutral2345.1%
Bearish12.0%
1 unmapped firm rating excluded from the percentages.
The Procter & Gamble Company · PG · FY2025 Q2 · Calendar Q1 2025
P&G Maintains FY2025 Guidance as China Improves and Innovation Broadens
The supplied analysis supports a measured constructive view of P&G’s operating trajectory: broad category growth, innovation and productivity are positive signals, while improving but still-negative China sales, FX, commodities and demand uncertainty limit confidence in the durability of earnings growth.
Reported Before market openNYSEConsumer Defensive
$373.21B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $1.89
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $21.72B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+1.9%
Event window
SPY move
+0.6%
Same window
Abnormal move
+1.3%
Stock minus SPY
Volume
2.0×
Versus trailing sessions
Subsequent drift
+1.5%
Up to 20 sessions
PGSPY benchmark
Ask FN2 about PG FY2025 Q2
Transcript, numbers and history already loaded
What drove PG's +1.9% move after FY2025 Q2 earnings?What changed in PG's guidance and outlook in FY2025 Q2?Give me the bull and bear case for PG after FY2025 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Versus the prior quarter, organic sales growth increased from 2% to 3%, Greater China’s decline improved from 15% to 3%, and SK-II returned to growth at 5%. Management continued to emphasize innovation and productivity while keeping fiscal 2025 guidance unchanged.
Guidance delta
Maintained: fiscal 2025 guidance remained at 3–5% organic sales growth and 5–7% core EPS growth, with 90% cash-flow productivity targeted.
Key takeaways
- Q2 organic sales rose 3%, with nine of ten categories posting growth.
- Greater China organic sales declined 3%, an improvement from the prior quarter’s 15% decline; SK-II grew 5%.
- Management highlighted innovation across Tide, Oral-B and other core brands, alongside productivity and cost-savings programs.
- The main offsets remain FX, commodities, supply-chain and regional demand risks.
Management priorities
- Expand innovation across core brands, including Tide Oxi Boost pods, Oral-B iO2 and Tide EVO.
- Continue productivity and cost-savings programs to support margins and cash-flow productivity.
- Pursue recovery in Greater China, including through premium SK-II performance.
- Maintain volume, share and penetration initiatives across North America, Europe and Latin America.
Follow PG with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$161.02Current
$40Low
$160.91Average
$192High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 25, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Wells Fargo | Overweight | Overweight | Maintain | Oct 23, 2026 |
| UBS | Buy | Buy | Maintain | Oct 23, 2026 |
| TD Cowen | Hold | Hold | Maintain | Oct 23, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Oct 23, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Oct 23, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Oct 23, 2026 |
| Freedom Broker | Buy | Hold | Upgrade | Oct 23, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Oct 23, 2026 |
| Citigroup | Buy | Buy | Maintain | Oct 23, 2026 |
| BNP Paribas | Outperform | Outperform | Maintain | Oct 23, 2026 |
| Argus Research | Hold | Buy | Downgrade | Aug 7, 2026 |
| HSBC | Hold | Buy | Downgrade | Jul 30, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 21, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jul 10, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Apr 8, 2026 |
| Deutsche Bank | Hold | Hold | Maintain | Mar 30, 2026 |
| Jefferies | Buy | Hold | Upgrade | Dec 17, 2025 |
| Raymond James | Outperform | Outperform | Maintain | Oct 20, 2025 |
| Truist Securities | Buy | Buy | Maintain | Apr 25, 2025 |
| Stifel | Hold | Hold | Maintain | Jan 23, 2025 |
| DA Davidson | Buy | Buy | Maintain | Jan 23, 2025 |
| DZ Bank | Buy | Hold | Upgrade | Aug 29, 2024 |
| Bernstein | Market Perform | Market Perform | Maintain | Oct 12, 2023 |
| Wolfe Research | Outperform | Outperform | Maintain | Nov 22, 2022 |
| Credit Suisse | Neutral | Neutral | Maintain | Nov 15, 2022 |
| Goldman Sachs | Neutral | Buy | Downgrade | Oct 10, 2022 |
| Independent Research | Buy | Hold | Upgrade | Jan 22, 2021 |
| Berenberg | Hold | Sell | Upgrade | Jan 24, 2019 |
| Bank of America | Buy | Buy | Maintain | Jan 8, 2019 |
| Macquarie | Outperform | Outperform | Maintain | Oct 22, 2018 |
| Atlantic Equities | Overweight | Overweight | Maintain | Sep 20, 2018 |
| B. Riley FBR | Neutral | Buy | Downgrade | May 5, 2018 |
| Stifel Nicolaus | Hold | Hold | Maintain | Apr 20, 2018 |
| Argus | Hold | Buy | Downgrade | Apr 20, 2018 |
| B. Riley Securities | Neutral | Buy | Downgrade | Mar 6, 2017 |
| SunTrust Robinson Humphrey | Hold | Buy | Downgrade | Dec 22, 2016 |
| CLSA | Outperform | Outperform | Maintain | Oct 26, 2016 |
| Argus Capital | Buy | Hold | Upgrade | Oct 12, 2016 |
| Johnson Rice | Buy | Accumulate | Maintain | Aug 26, 2016 |
| Sterne Agee CRT | Buy | Neutral | Upgrade | Feb 16, 2016 |
| Sterne Agee | Buy | Neutral | Upgrade | Feb 16, 2016 |
| GMP Securities | Hold | Hold | Maintain | Feb 3, 2016 |
| Hilliard Lyons | Neutral | Upgrade | Jun 4, 2015 | |
| Societe Generale | Hold | Buy | Downgrade | Apr 29, 2015 |
| BTIG Research | Neutral | Neutral | Maintain | Dec 30, 2014 |
| Canaccord Genuity | Hold | Buy | Downgrade | Nov 17, 2014 |
| Standpoint Research | Hold | Sell | Upgrade | Jan 31, 2014 |
| Exane BNP Paribas | Underperform | Underperform | Maintain | Sep 11, 2013 |
| Oracle Investment Research | Hold | Sell | Upgrade | May 24, 2013 |
| Tigress Financial | Neutral | Neutral | Maintain | Feb 25, 2013 |
| BMO Capital | Outperform | Outperform | Maintain | Oct 26, 2012 |
| Bank oferica | Buy | Buy | Maintain | Feb 28, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $161.02. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Analyst unavailable | $190 | $161.64 | +18.0% | Oct 23, 2026 |
| UBS | Analyst unavailable | $166 | $161.8 | +3.1% | Oct 23, 2026 |
| RBC Capital | Nik Modi | $169 | $165.59 | +5.0% | Oct 23, 2026 |
| Morgan Stanley | Analyst unavailable | $185 | $165.59 | +14.9% | Oct 23, 2026 |
| Goldman Sachs | Analyst unavailable | $161 | $165.59 | -0.0% | Oct 22, 2026 |
| RBC Capital | Nik Modi | $166 | $147.36 | +3.1% | Oct 6, 2026 |
| Evercore ISI | Analyst unavailable | $166 | $145.94 | +3.1% | Oct 6, 2026 |
| Bernstein | Cristian Rios | $149 | $146.25 | -7.5% | Aug 24, 2026 |
| HSBC | Diego Serrano | $149 | $146.15 | -7.5% | Jul 30, 2026 |
| HSBC | Analyst unavailable | $142 | $146.15 | -11.8% | Jul 29, 2026 |
| Barclays | Analyst unavailable | $152 | $149.14 | -5.6% | Jul 21, 2026 |
| Bernstein | Analyst unavailable | $156 | $148.32 | -3.1% | Jun 11, 2026 |
| UBS | Analyst unavailable | $172 | $148.46 | +6.8% | Apr 27, 2026 |
| Deutsche Bank | Steve Powers | $163 | $148.63 | +1.2% | Apr 27, 2026 |
| Evercore ISI | Robert Ottenstein | $162 | $148.11 | +0.6% | Apr 27, 2026 |
| Wells Fargo | Analyst unavailable | $164 | $148.11 | +1.9% | Apr 27, 2026 |
| Barclays | Analyst unavailable | $146 | $143.86 | -9.3% | Apr 14, 2026 |
| RBC Capital | Analyst unavailable | $167 | $146.66 | +3.7% | Apr 9, 2026 |
| Piper Sandler | Analyst unavailable | $142 | $144.9 | -11.8% | Apr 8, 2026 |
| Wells Fargo | Analyst unavailable | $177 | $160.07 | +9.9% | Feb 17, 2026 |
| UBS | Analyst unavailable | $170 | $151.06 | +5.6% | Jan 23, 2026 |
| Wells Fargo | Chris Carey | $165 | $149.93 | +2.5% | Jan 23, 2026 |
| Barclays | Lauren Lieberman | $155 | $144.37 | -3.7% | Jan 16, 2026 |
| UBS | Peter Grom | $161 | $146.54 | -0.0% | Jan 14, 2026 |
| Piper Sandler | Analyst unavailable | $150 | $139.91 | -6.8% | Jan 7, 2026 |
| Wells Fargo | Analyst unavailable | $158 | $140.04 | -1.9% | Jan 5, 2026 |
| Jefferies | Analyst unavailable | $179 | $145.21 | +11.2% | Dec 16, 2025 |
| Barclays | Analyst unavailable | $151 | $143.45 | -6.2% | Dec 8, 2025 |
| Morgan Stanley | Analyst unavailable | $175 | $151.46 | +8.7% | Oct 27, 2025 |
| UBS | Peter Grom | $176 | $150.92 | +9.3% | Oct 8, 2025 |
| Barclays | Lauren Lieberman | $153 | $153.65 | -5.0% | Oct 1, 2025 |
| Barclays | Analyst unavailable | $164 | $152.88 | +1.9% | Jul 31, 2025 |
| UBS | Peter Grom | $180 | $154.94 | +11.8% | Jul 30, 2025 |
| Redburn Partners | Edward Lewis | $161 | $159.98 | -0.0% | May 1, 2025 |
| Morgan Stanley | Dara Mohsenian | $180 | $160.06 | +11.8% | Apr 25, 2025 |
| Barclays | Lauren Lieberman | $159 | $164.74 | -1.3% | Jan 23, 2025 |
| Jefferies | Kaumil Gajrawala | $174 | $175.68 | +8.1% | Dec 5, 2024 |
| Stifel Nicolaus | Mark Astrachan | $167 | $176.28 | +3.7% | Nov 22, 2024 |
| Truist Financial | Bill Chappell | $180 | $169.64 | +11.8% | Oct 21, 2024 |
| RBC Capital | Nik Modi | $164 | $169 | +1.9% | Oct 21, 2024 |
| D.A. Davidson | Linda Bolton Weiser | $160 | $169.02 | -0.6% | Oct 21, 2024 |
| Raymond James | Olivia Tong | $190 | $171.28 | +18.0% | Oct 21, 2024 |
| D.A. Davidson | Linda Bolton Weiser | $159 | $169.27 | -1.3% | Oct 9, 2024 |
| Goldman Sachs | Bonnie Herzog | $164 | $168.88 | +1.9% | Oct 4, 2024 |
| Barclays | Lauren Lieberman | $163 | $173.55 | +1.2% | Sep 30, 2024 |
| Piper Sandler | Korinne Wolfmeyer | $174 | $173.77 | +8.1% | Sep 23, 2024 |
| BNP Paribas | Kevin Grundy | $192 | $177.02 | +19.2% | Sep 16, 2024 |
| Jefferies | Kaumil Gajrawala | $175 | $165.93 | +8.7% | Jul 24, 2024 |
| Stifel Nicolaus | Mark Astrachan | $161 | $167.96 | -0.0% | Jul 22, 2024 |
| Evercore ISI | Robert Ottenstein | $183 | $169.44 | +13.7% | Jul 18, 2024 |
| Deutsche Bank | Steve Powers | $176 | $168.53 | +9.3% | Jul 17, 2024 |
| BNP Paribas | Kevin Grundy | $187 | $168.26 | +16.1% | Jun 24, 2024 |
| Argus Research | Chris Graja | $185 | $162.88 | +14.9% | Apr 25, 2024 |
| Barclays | Lauren Lieberman | $170 | $160.54 | +5.6% | Apr 23, 2024 |
| Bernstein | Alexia Howard | $40 | $151.38 | -75.2% | Nov 24, 2023 |
| Morgan Stanley | Dara Mohsenian | $174 | $146.26 | +8.1% | Oct 18, 2023 |
| Raymond James | Olivia Tong | $170 | $150.25 | +5.6% | Jan 13, 2023 |
| J.P. Morgan | Analyst unavailable | $150 | $149.86 | -6.8% | Jan 13, 2023 |
| Wells Fargo | Analyst unavailable | $168 | $150.62 | +4.3% | Jan 3, 2023 |
| Deutsche Bank | Analyst unavailable | $162 | $148.47 | +0.6% | Dec 6, 2022 |
| Wells Fargo | Analyst unavailable | $155 | $140.49 | -3.7% | Nov 16, 2022 |
| Credit Suisse | Analyst unavailable | $130 | $141.66 | -19.3% | Nov 15, 2022 |
| Raymond James | Olivia Tong | $155 | $124.43 | -3.7% | Oct 12, 2022 |
| Goldman Sachs | Jason English | $143 | $124.27 | -11.2% | Oct 9, 2022 |
| Wells Fargo | Analyst unavailable | $150 | $126.25 | -6.8% | Oct 3, 2022 |
| Barclays | Lauren Lieberman | $154 | $149.81 | -4.4% | Aug 18, 2022 |
| Truist Financial | Analyst unavailable | $160 | $142.6 | -0.6% | Aug 1, 2022 |
| J.P. Morgan | Analyst unavailable | $156 | $139.77 | -3.1% | Jul 21, 2022 |
| Deutsche Bank | Analyst unavailable | $157 | $135.81 | -2.5% | Jun 21, 2022 |
| Deutsche Bank | Steve Powers | $171 | $132.36 | +6.2% | Jun 19, 2022 |
| Wells Fargo | Chris Carey | $170 | $145.46 | +5.6% | Jun 6, 2022 |
| Barclays | Analyst unavailable | $157 | $141.79 | -2.5% | May 23, 2022 |
| Credit Suisse | Kaumil Gajrawala | $150 | $161.74 | -6.8% | Apr 26, 2022 |
| Barclays | Analyst unavailable | $176 | $161.39 | +9.3% | Apr 22, 2022 |
| Deutsche Bank | Analyst unavailable | $177 | $164.54 | +9.9% | Apr 21, 2022 |
| Raymond James | Analyst unavailable | $180 | $163.65 | +11.8% | Apr 21, 2022 |
| UBS | Peter Grom | $160 | $158.52 | -0.6% | Apr 19, 2022 |
| Raymond James | Olivia Tong | $175 | $159.49 | +8.7% | Apr 11, 2022 |
| Goldman Sachs | Jason English | $173 | $155.09 | +7.4% | Apr 1, 2022 |
| Truist Financial | Bill Chappell | $175 | $150.82 | +8.7% | Mar 23, 2022 |
| UBS | Peter Grom | $163 | $162 | +1.2% | Jan 20, 2022 |
| Morgan Stanley | Dara Mohsenian | $177 | $162 | +9.9% | Jan 20, 2022 |
| Stifel Nicolaus | Mark Astrachan | $148 | $161.13 | -8.1% | Jan 19, 2022 |
| Jefferies | Kevin Grundy | $187 | $161.13 | +16.1% | Jan 19, 2022 |
| Wells Fargo | Christopher Carey | $180 | $163.33 | +11.8% | Jan 5, 2022 |
| Bank of America Securities | Bryan Spillane | $160 | $137.73 | -0.6% | Oct 5, 2021 |
| Independent Research | Lars Lusebrink | $154 | $140.79 | -4.4% | Aug 4, 2021 |
| Credit Suisse | Kaumil Gajrawala | $145 | $140.25 | -9.9% | Aug 2, 2021 |
| DZ BANK AG | Michael Pohn | $119 | $133.58 | -26.1% | Apr 21, 2021 |
Track every rating change on PG the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationThe Procter & Gamble Company, commonly referred to as P&G, is a global enterprise that supplies a broad spectrum of branded consumer products to markets worldwide. The company's operations are divided into five main business divisions: Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine & Family Care. The Beauty segment offers an assortment of hair care products, including conditioners, shampoos, styling aids, and treatments, under popular names like Head & Shoulders, Herbal Essences, Pantene, and Rejoice. It also features antiperspirants, deodorants, personal cleansing solutions, and skin care items from brands such as Olay, Old Spice, Safeguard, Secret, and SK-II. Within the Grooming division, P&G provides a range of shave care products and grooming appliances, prominently featuring brands like Braun, Gillette, and Venus. The Health Care unit encompasses oral hygiene essentials, including toothbrushes, toothpastes, and other dental care products sold under the Crest and Oral-B brand names.…
Historical context
All PG earningsLatest beats and misses
Who reports nextBeat on EPS
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
- FCNCOFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- FCNCPFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- RDYFY2027 Q2 · October 23, 2026+24.0% EPS-0.2% move
- SLBFY2026 Q3 · October 23, 2026+3.7% EPS+7.1% move
Missed on EPS
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
- HBANMFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
Get the PG recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-01-08T00:01:14.930234+00:00
- Polygon adjusted daily market bars · 2026-10-25T14:30:42.034959+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-25T14:30:42.031938+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-25. For educational purposes only; not investment advice.